Indications for External Beam Radiation vs Brachytherapy in Prostate Cancer Management
For low-risk prostate cancer, either EBRT or brachytherapy alone are equivalent options; for favorable intermediate-risk disease, either modality alone or in combination is appropriate; however, for unfavorable intermediate-risk and high-risk disease, EBRT combined with brachytherapy boost (plus ADT for high-risk) provides superior biochemical control compared to either modality alone. 1, 2
Risk-Stratified Treatment Algorithm
Low-Risk Disease
- Either EBRT or brachytherapy monotherapy are acceptable options 1, 2
- Both modalities demonstrate equivalent oncologic outcomes
- Choice depends primarily on patient factors (see contraindications below)
Favorable Intermediate-Risk Disease
- EBRT alone, brachytherapy alone, OR combination EBRT + brachytherapy are all reasonable 1, 2
- Low-intermediate risk patients (Gleason 7 with PSA <10 ng/mL OR Gleason 6 with PSA 10-20 ng/mL) can receive LDR brachytherapy monotherapy 2
- Recent high-quality RCT data (NRG RTOG 0232) showed no benefit to adding EBRT to brachytherapy alone for intermediate-risk disease, though this increased late grade 2+ toxicity from 25.8% to 42.8% (p<0.0001) 3
Unfavorable Intermediate-Risk Disease
- EBRT + brachytherapy boost with or without ADT is preferred over either modality alone 4, 2
- Meta-analysis demonstrates brachytherapy boost improves 5-year biochemical progression-free survival (HR 0.49,95% CI 0.37-0.66, p<0.01) 5
- Recent NCDB analysis showed brachytherapy alone with ADT had comparable survival to EBRT with ADT (HR 0.90,95% CI 0.84-0.97, p=0.009), though EBRT+brachytherapy remains guideline-recommended 6, 7
High-Risk and Very High-Risk Disease
- EBRT combined with brachytherapy boost PLUS 24-36 months of ADT 1, 4
- Combination EBRT + brachytherapy reduces disease-specific mortality compared to EBRT alone (HR 0.77,95% CI 0.66-0.90) in high-risk patients 4
- Brachytherapy alone is not recommended as monotherapy for high-risk disease 4
Critical Contraindications and Patient Selection
Absolute Contraindications to Brachytherapy
- Previous large transurethral resection of prostate (TURP) 8
- Previous pelvic radiation 1
- Inflammatory bowel disease 1
Relative Contraindications to Brachytherapy
- Prostate volume >50-60 cm³ 8
- Median lobe hypertrophy 8
- Moderate to severe baseline obstructive urinary symptoms 1, 2
- Previous limited TURP 8
Critical counseling point: Brachytherapy has similar effects as EBRT regarding erectile dysfunction and proctitis, but specifically exacerbates urinary obstructive symptoms 1. Patients with pre-existing lower urinary tract symptoms should preferentially receive EBRT or surgical approaches.
Key Nuances in Evidence
The 2023 NRG RTOG 0232 trial represents the highest-quality recent evidence, showing that for intermediate-risk disease, brachytherapy alone achieved equivalent 5-year freedom from progression (85.5%) compared to combination EBRT + brachytherapy (88.0%), with significantly less toxicity 3. This challenges older recommendations favoring combination therapy for all intermediate-risk patients.
However, for unfavorable intermediate-risk specifically, multiple retrospective analyses suggest benefit to combination therapy 6, 7, and the 2018 AUA/ASTRO guidelines maintain that either approach is acceptable 1.
For very high-risk disease, recent multicenter data showed no difference in prostate cancer-specific mortality between EBRT alone (with ≥24 months ADT) versus EBRT + brachytherapy boost (with ≥12 months ADT), suggesting that adequate systemic therapy duration may be more important than local dose escalation in this population 9.
Quality Assurance Requirement
Brachytherapy should only be performed at centers following strict quality-assurance standards 2. Suboptimal implant dosimetry may negate the benefits of brachytherapy, as suggested by population-level analyses showing variable outcomes 7.